Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biapenem.

Caroline M Perry1, Tim Ibbotson

  • 1Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz

Drugs
|October 17, 2002
PubMed
Summary
This summary is machine-generated.

Biapenem is a novel carbapenem antibiotic effective against a wide range of bacteria. It demonstrates good clinical efficacy and tolerability, without needing a dihydropeptidase-I inhibitor.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Drugs·2014
Same author

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Drugs·2014
Same author

Rivaroxaban: a review of its use in the treatment of deep vein thrombosis or pulmonary embolism and the prevention of recurrent venous thromboembolism.

Drugs·2014
Same author

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults.

Drugs·2013
Same author

Simeprevir: first global approval.

Drugs·2013
Same author

Raltegravir: a review of its use in the management of HIV-1 infection in children and adolescents.

Paediatric drugs·2013
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Biapenem is a new parenteral carbapenem with broad-spectrum antibacterial activity.
  • It exhibits greater stability against human renal dihydropeptidase-I (DHP-I) compared to other carbapenems.
  • This stability negates the need for coadministration with a DHP-I inhibitor.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of biapenem.
  • To assess its pharmacokinetic profile and tissue penetration.
  • To compare its performance against established treatments like imipenem/cilastatin.

Main Methods:

  • Randomized, nonblind or double-blind clinical trials were conducted.
  • Adult patients with specific infections were treated with biapenem.

Related Experiment Videos

  • Clinical and bacteriological outcomes were assessed.

    • Main Results:

    • Biapenem demonstrated broad in vitro activity against Gram-negative, Gram-positive, aerobic, and anaerobic bacteria, including beta-lactamase producers.
    • The drug showed wide distribution into tissues and body fluids after intravenous administration.
    • Clinical and bacteriological efficacy was comparable to imipenem/cilastatin in treating intra-abdominal, lower respiratory, and urinary tract infections.

    Conclusions:

    • Biapenem is an effective and well-tolerated parenteral carbapenem antibiotic.
    • Its stability to DHP-I offers a therapeutic advantage.
    • It represents a viable treatment option for various bacterial infections.